COMPARISON OF MULTIPLE-DRUG THERAPY REGIMENS FOR HIV-RELATED DISSEMINATED MYCOBACTERIUM-AVIUM COMPLEX DISEASE

被引:11
作者
KISSINGER, P [1 ]
CLARK, R [1 ]
MORSE, A [1 ]
BRANDON, W [1 ]
机构
[1] OFF PUBL HLTH OFF STATE LOUISIANA,NEW ORLEANS,LA
来源
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY | 1995年 / 9卷 / 02期
关键词
MYCOBACTERIUM AVIUM COMPLEX; MULTIDRUG THERAPY; EFFECTS ON SURVIVAL;
D O I
10.1097/00042560-199506000-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In June 1993, the United States Public Health Service (USPHS) made recommendations for treatment of disseminated Mycobacterium avium complex (MAC) in patients infected with the human immunodeficiency syndrome (HIV). It was suggested that every treatment regimen include either azithromycin or clarithromycin plus one or more of the following drugs: ethambutol, clofazimine, rifabutin, rifampin, ciprofloxacin, or amikacin. This study compares the effect of multiple drug therapy regimens on the survival of patients of the HIV outpatient department of the Medical Center of New Orleans, Louisiana. A retrospective chart review of 122 confirmed cases of MAC was conducted. Three treatment groups were considered: no/monotreatment (n = 40), multitreatment without clarithromycin (n = 32), and multitreatment with clarithromycin (n = 50). Azithromycin, amikacin, and rifabutin were not used in this clinic during the study period. Both multitreatment without clarithromycin (p < 0.03) and multitreatment with clarithromycin (p < 0.005) were significantly protective for survival after adjusting for CD4 cell count at time of diagnosis, nonadherence to treatment, number of concomitant opportunistic infections at diagnosis, and weight loss >10%. Neither of the groups that received multidrug therapy were significantly less likely to have MAC-related symptoms than the no/mono group at 3 and 6 months postdiagnosis. These findings support the USPHS recommendation for multiple drug treatment either with or without clarithromycin. Prospective controlled clinical trials will clarify the optimal regimen for disseminated MAC disease.
引用
收藏
页码:133 / 137
页数:5
相关论文
共 23 条
[1]   EFFECT OF COMBINED THERAPY WITH ANSAMYCIN, CLOFAZIMINE, ETHAMBUTOL, AND ISONIAZID FOR MYCOBACTERIUM-AVIUM INFECTION IN PATIENTS WITH AIDS [J].
AGINS, BD ;
BERMAN, DS ;
SPICEHANDLER, D ;
ELSADR, W ;
SIMBERKOFF, MS ;
RAHAL, JJ .
JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (04) :784-787
[2]  
Chaisson R., 1993, AIDS Clinical Care, V5, P1
[3]   INCIDENCE AND NATURAL-HISTORY OF MYCOBACTERIUM-AVIUM COMPLEX INFECTIONS IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE TREATED WITH ZIDOVUDINE [J].
CHAISSON, RE ;
MOORE, RD ;
RICHMAN, DD ;
KERULY, J ;
CREAGH, T .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 146 (02) :285-289
[4]  
CHAISSON RE, 1992, 32ND INT C ANT AG CH, P891
[5]  
DAUTZENBERG B, 1992, AM REV RESPIR DIS, V144, P564
[6]   DISSEMINATED MYCOBACTERIUM-AVIUM COMPLEX INFECTION - CLINICAL-IDENTIFICATION AND EPIDEMIOLOGIC TRENDS [J].
HAVLIK, JA ;
HORSBURGH, CR ;
METCHOCK, B ;
WILLIAMS, PP ;
FANN, SA ;
THOMPSON, SE .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (03) :577-580
[7]  
HORSBURGH C R, 1991, American Review of Respiratory Disease, V143, pA115
[8]   SURVIVAL OF PATIENTS WITH ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME AND DISSEMINATED MYCOBACTERIUM-AVIUM COMPLEX INFECTION WITH AND WITHOUT ANTIMYCOBACTERIAL CHEMOTHERAPY [J].
HORSBURGH, CR ;
HAVLIK, JA ;
ELLIS, DA ;
KENNEDY, E ;
FANN, SA ;
DUBOIS, RE ;
THOMPSON, SE .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (03) :557-559
[9]   THE EPIDEMIOLOGY OF DISSEMINATED NONTUBERCULOUS MYCOBACTERIAL INFECTION IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) [J].
HORSBURGH, CR ;
SELIK, RM .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 139 (01) :4-7
[10]   CURRENT CONCEPTS - MYCOBACTERIUM-AVIUM COMPLEX INFECTION IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
HORSBURGH, CR .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (19) :1332-1338